| |
|
|
|
Powerpoint Presentation Downloads: 3691
|
Rating : 
|
|
|
|
|
Monoclonal Antibody Therapy for Cancer . Rituximab anti-CD20 lymphoma. Herceptin anti-her2/neu breast cancer. Myelotarg anti-CD33 AML. Campath anti-CD52 CLL
|
|
|
|
|
|
|
|
Powerpoint Presentation Downloads: 1884
|
|
Rating :
|
|
|
|
|
Shapiro, MD discusses new clinical trial data on alemtuzumab and tacrolimus monotherapy after renalof a short desensitization protocol of IVIG and rituximab in renal transplant
|
|
|
|
|
|
|
|
Powerpoint Presentation Downloads: 1868
|
|
Rating :
|
|
|
|
|
review of the current use of rituximab in low grade non-hodgkin linphoma, in portuguese- Slides
|
|
|
|
|
|
|
|
Powerpoint Presentation Downloads: 1677
|
|
Rating :
|
|
|
|
|
Monoclonal antibodiesUnconjugated Rituximab(Rituxan)lymphoma (CD20) Trastuzumab (Herceptin)breast (her2)
|
|
|
|
|
|
|
|
Powerpoint Presentation Downloads: 1080
|
|
Rating :
|
|
|
|
|
Rituximab: A Giant Leap in the Management of B-Cell Lymphoma ... defer treatment if asymptomatic (“watch-and-wait”) several chemotherapy options if symptomatic
|
|
|
|
|
|
|
|
Powerpoint Presentation Downloads: 779
|
|
Rating :
|
|
|
|
|
images.medscape.com/images/538/404/rituximab.ppt
|
|
|
|
|
|
|
|
Powerpoint Presentation Downloads: 607
|
|
Rating :
|
|
|
|
|
Evaluate the safety and efficacy of B lymphocyte depletion therapy in refractory systemic lupus erythematosus (SLE); METHODS: Six female patients with
|
|
|
|
|
|
|
|
Powerpoint Presentation Downloads: 558
|
|
Rating :
|
|
|
|
|
Rituximab in Rheumatoid Arthritis: Phase IIa Study (Edwards et al, 2004 NEJM) Design and Treatment Groups *Patients on all arms received appropriate
|
|
|
|
|
|
|
|
Powerpoint Presentation Downloads: 544
|
|
Rating :
|
|
|
|
|
median age: 46 y; median time of disease duration: 34 mo; 54% of patients splenectomized; median number of previous treatment lines: 3 …
|
|
|
|
|
|
|
|
Powerpoint Presentation Downloads: 444
|
|
Rating :
|
|
|
|
|
PowerPoint Presentation on progress in immune therapy rituximab or PowerPoint Presentation on
|
|
|
|
|
